Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 30

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders

Ferrer, Alejandro, Mangaonkar, Abhishek A., Patnaik, Mrinal M.·2022·Current Hematologic Malignancy Reports
DOI 10.1007/s11899-022-00662-8PMC PMC9077347
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11899-022-00662-8

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 34

  1. Niewisch MR, Giri N, McReynolds LJ, Alsaggaf R, Bhala S, Alter BP, et al. Disease progression and clinical outcomes in telomere biology disorders. Blood. 2022;139(12):1807–19. · DOI
  2. Mangaonkar AA, Patnaik MM. Short telomere syndromes in clinical practice: bridging bench and bedside. Mayo Clin Proc. 2018;93(7):904–16. · DOI
  3. Mangaonkar AA, Ferrer A, Pinto EVF, Cousin MA, Kuisle RJ, Klee EW, et al. Clinical correlates and treatment outcomes for patients with short telomere syndromes. Mayo Clin Proc. 2018;93(7):834–9. · DOI
  4. Alter BP, Giri N, Savage SA, Rosenberg PS. 2018 Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up. Haematologica. 103(1):30–9. Description of the clinical outcomes of the TBD cohort assembled by the NIH describing higher risk to develop MN and specific characteristics of these patients. · DOI
  5. Schratz KE, Haley L, Danoff SK, Blackford AL, DeZern AE, Gocke CD, et al. 2020 Cancer spectrum and outcomes in the Mendelian short telomere syndromes. Blood. 135(22):1946–56. Description of the clinical outcomes of the TBD cohort assemled at Johns Hopkins. First report indicating that TBD patients present with increased CH and a different mutational signature compared to ARCH. · DOI
  6. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. · DOI · Paper page
  7. Schratz KE, Armanios M. Cancer and myeloid clonal evolution in the short telomere syndromes. Curr Opin Genet Dev. 2020;60:112–8. · DOI
  8. Gutierrez-Rodrigues F, Groarke EM, Clé DV, Patel BA, Donaires FS, Spitofsky N, et al. 2021 Clonal hematopoiesis in telomere biology disorders associates with the underlying germline defect and somatic mutations in POT1, PPM1D, and TERT promoter. Blood. 138(Supplement 1):1111-. Description in more detail of the somatic mutational landscape observed in the larger number of TBD patients to date. Possible association between specific somatic events and germline mutations. · DOI
  9. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–87. · DOI · Paper page
  10. Warren JT, Link DC. Clonal hematopoiesis and risk for hematologic malignancy. Blood. 2020;136(14):1599–605.
  11. Menendez-Gonzalez JB, Rodrigues NP. Exploring the associations between clonal hematopoiesis of indeterminate potential, myeloid malignancy, and atherosclerosis. Methods Mol Biol. 2022;2419:73–88. · DOI
  12. Nassour J, Radford R, Correia A, Fuste JM, Schoell B, Jauch A, et al. Autophagic cell death restricts chromosomal instability during replicative crisis. Nature. 2019;565(7741):659–63. · DOI · Paper page
  13. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–98. · DOI · Paper page
  14. DeZern AE, Malcovati L, Ebert BL. CHIP, CCUS, and other acronyms: definition, implications, and impact on practice. Am Soc Clin Oncol Educ Book. 2019;39:400–10. · DOI
  15. Steensma DP. The clinical challenge of idiopathic cytopenias of undetermined significance (ICUS) and clonal cytopenias of undetermined significance (CCUS). Curr Hematol Malig Rep. 2019;14(6):536–42. · DOI
  16. Fuster JJ, Zuriaga MA, Zorita V, MacLauchlan S, Polackal MN, Viana-Huete V, et al. TET2-loss-of-function-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity. Cell Rep. 2020;33(4): 108326. · DOI · Paper page
  17. Bolton KL, Koh Y, Foote MB, Im H, Jee J, Sun CH, et al. Clonal hematopoiesis is associated with risk of severe COVID-19. Nat Commun. 2021;12(1):5975. · DOI
  18. Mitchell SR, Gopakumar J, Jaiswal S. Insights into clonal hematopoiesis and its relation to cancer risk. Curr Opin Genet Dev. 2021;66:63–9. · DOI
  19. Jaiswal S. Clonal hematopoiesis and nonhematologic disorders. Blood. 2020;136(14):1606–14.
  20. Zink F, Stacey SN, Norddahl GL, Frigge ML, Magnusson OT, Jonsdottir I, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130(6):742–52. · DOI · Paper page
  21. Loh PR, Genovese G, Handsaker RE, Finucane HK, Reshef YA, Palamara PF, et al. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature. 2018;559(7714):350–5. · DOI · Paper page
  22. Rossi M, Meggendorfer M, Zampini M, Tettamanti M, Riva E, Travaglino E, et al. Clinical relevance of clonal hematopoiesis in persons aged >/=80 years. Blood. 2021;138(21):2093–105. · DOI
  23. Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21(3):374-82.e4. · DOI · Paper page
  24. Schratz KE, Gaysinskaya V, Cosner ZL, DeBoy EA, Xiang Z, Kasch-Semenza L, et al. 2021 Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders. J Clin Invest. 131(18). Study of genetic rescue in the development of MDS/AML in TBD patients. · DOI
  25. Revy P, Kannengiesser C, Fischer A. Somatic genetic rescue in Mendelian haematopoietic diseases. Nat Rev Genet. 2019;20(10):582–98. · DOI
  26. Maryoung L, Yue Y, Young A, Newton CA, Barba C, van Oers NS, et al. Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations. J Clin Invest. 2017;127(3):982–6. · DOI
  27. Gutierrez-Rodrigues F, Donaires FS, Pinto A, Vicente A, Dillon LW, Cle DV, et al. Pathogenic TERT promoter variants in telomere diseases. Genet Med. 2019;21(7):1594–602. · DOI
  28. Alter BP. Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Blood. 2017;130(21):2257–64. · DOI
  29. Myers KC, Furutani E, Weller E, Siegele B, Galvin A, Arsenault V, et al. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. Lancet Haematol. 2020;7(3):e238–46. · DOI
  30. Ip E, McNeil C, Grimison P, Scheinberg T, Tudini E, Ho G, et al. 2021 Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to FANCD1/BRCA2 during adulthood: description of an emerging phenotype. J Med Genet. · DOI
  31. Peffault de Latour R, Soulier J. How I treat MDS and AML in Fanconi anemia. Blood. 2016;127(24):2971–9. · DOI
  32. Myllymaki M, Redd R, Reilly CR, Saber W, Spellman SR, Gibson CJ, et al. Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood. 2020;136(26):3070–81. · DOI
  33. Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant. 2013;19(8):1238–43. · DOI
  34. Testori A. Short telomere syndromes, biological aging, and hematopoietic stem cell transplantation. Mayo Clin Proc. 2018;93(11):1684–5. · DOI

Cited by

Metadata

Authors
Ferrer, A., Mangaonkar, A. A., & Patnaik, M. M.
Venue
Current Hematologic Malignancy Reports
Publisher
Springer Science and Business Media LLC
Published
2022-05-07
Volume
17
Issue
3
Pages
61-68
ISSN
  • 1558-8211
  • 1558-822X
DOI
10.1007/s11899-022-00662-8
PMC
PMC9077347
Cited by
30
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review